**Core Concept**
Lanatoprost is a prostaglandin analog used in the treatment of glaucoma. It works by decreasing intraocular pressure (IOP) through a specific mechanism.

**Why the Correct Answer is Right**
Lanatoprost primarily acts by increasing the outflow of aqueous humor through the uveoscleral pathway. This results in a decrease in IOP. The uveoscleral pathway is a secondary outflow route in addition to the conventional trabecular meshwork pathway. Lanatoprost stimulates the uveoscleral pathway, leading to a reduction in IOP.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because lanatoprost does not primarily act by increasing the outflow through the trabecular meshwork pathway, although it may have a minor effect on this pathway.
**Option B:** This option is incorrect because lanatoprost is not a carbonic anhydrase inhibitor, which is a different class of medication used to treat glaucoma.
**Option C:** This option is incorrect because lanatoprost does not primarily act by decreasing aqueous humor production, although it may have a minor effect on this process.

**Clinical Pearl / High-Yield Fact**
Lanatoprost is a member of the prostaglandin analog class, which also includes other medications like bimatoprost and travoprost. These medications are all used to decrease IOP in glaucoma patients and work by increasing the outflow of aqueous humor through the uveoscleral pathway.

**Correct Answer: C. Decreasing aqueous humor outflow through the uveoscleral pathway.**